Blog

Bollywood actress Shilpa Shetty has made an undisclosed investment in D2C nutraceutical brands-Fast&Up and Chicnutrix that run under the parent company Fullife Healthcare.

As part of the deal, Shetty has also joined these brands as a brand ambassador and will work towards strengthening and promoting health and self-care in India.

“Fast&Up and Chicnutrix have created some of the greatest products out there. I am extremely excited to witness their growth journey. Our lifestyle today is fast-paced and it is difficult to keep up with all required nutrients or vitamins that are essential on a daily basis for the body, hair, skin, energy and general well-being. Their products totally suit today’s demands,” Shilpa Shetty said.

Founded in 2015 by Vijayaraghavan Venugopal and Varun Khanna, Fullife Healthcare, which is the parent company of Fast&Up and Chicnutrix, has a presence in India and across 21 international markets including Europe, the UK and USA.

“With immense pleasure, we welcome Shilpa Shetty Kundra to our family of investors. Shilpa’s personal approach to holistic well-being resonates with our core values with Fast&Up and Chicnutrix. As a woman who herself is a firm believer in fitness and natural ingredients, she joins the brand with an authentic voice that helps spread this positive message of healthy living every day,” said Varun Khanna, CEO of Fullife Healthcare. 

Fullife Healthcare was previously backed by Indian cricketer Mayank Aggarwal and Bollywood actor Varun Dhawan.

In 2021, Fullife Healthcare secured $22 Mn in its Series C funding round from Morgan Stanley Private Equity Asia. So far, it raised a total of $37.8 Mn from investors. Its cap table includes Akash Prakash from Amansa Capital, Rakesh Jhunjhunwala, Sixth Sense Ventures, Bollywood actor Varun Dhawan and Indian Cricketer Mayank Agarwal, among others. 

In the D2C nutraceutical segment, Fast&Up and Chicnutrix are facing competition from the likes of Wellbeing Nutrition, Kapiva, Supply6, Trunativ and Auric, among others.

According to a report, India’s nutraceuticals market, which was pegged at $4 Bn, is likely to become an $18 Bn market by 2026. The industry is expected to grow at a CAGR of 35% by 2026.